Structure Therapeutics reported robust mid‑stage efficacy for its small‑molecule GLP‑1 candidate aleniglipron, with patients on higher doses losing as much as 14.2% of body weight at 36 weeks. The company ran two mid‑stage trials that showed placebo‑adjusted losses in double digits, positioning the oral candidate competitively against peptide and small‑molecule rivals. Safety signals complicated the readouts: investigators reported high rates of nausea (65%) and vomiting (32%), and an 11% discontinuation rate in one trial. Those tolerability data will shape dose selection, labeling discussions, and competitive positioning versus Lilly and Novo Nordisk. Regulators and partners will scrutinize whether efficacy can be preserved while improving GI tolerability. Investors and competitors will treat these findings as a critical data point in the crowded oral GLP‑1 race: the combination of strong weight loss and notable adverse events creates a clear development pathway but also a risk that may favor alternative formulations or titration strategies.